|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||102.45 - 104.22|
|52 Week Range||95.27 - 116.49|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||17.64|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||2.00 (1.95%)|
|1y Target Est||117.50|
Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.
Four Presentations Reveal Genetic Insights from Quest's Advanced Diagnostics SECAUCUS, N.J. , Oct. 16, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information ...
SECAUCUS, N.J., Oct. 10, 2018 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that its subsidiary, Summit Health Inc. ("Summit"), has completed the previously disclosed acquisition of the assets of Hooper Holmes, Inc. d/b/a Provant Health (HPHWQ) ("Provant Health"), a provider of employer health and wellness services focused on whole person wellness and care cost management. "This acquisition is wholly consistent with our accelerate growth strategy, and our goal to empower the health and wellness initiatives of employers and other organizations managing population health," said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics. "Quest's health and wellness solutions empower individuals and organizations with insights and actions to identify and change problem behaviors, and engage in needed medical and preventative care, leading to healthier lives.
The Add-On Deal Roundup: Oct. 10 MRI Software LLC, a Solon, Ohio-based provider of real-estate software backed by TA Associates and GI Partners, acquired IPM Software, a Pasadena, Texas, company that provides property management, accounting and compliance services for the affordable housing industry.
The GDN brings together leading diagnostics services providers to share expertise and drive worldwide diagnostics innovation SECAUCUS, N.J. , Oct. 10, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), ...
SECAUCUS, N.J., Oct. 9, 2018 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, announced today that it received the Gold Award in the 2018 Best Employers for Healthy Lifestyles awards from the National Business Group on Health (NBGH). The awards recognized 49 employers that have an exceptional commitment to improving the lives of their employees through their overall well-being, productivity and quality of life. The Gold Award is presented to member companies that have a strong commitment to holistic well-being and related metrics.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-483-9044 for domestic callers or 203-369-1586 for international callers, no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on October 23, 2018 until midnight Eastern Time on November 6, 2018. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
SECAUCUS, N.J. and BANGALORE, India, Oct. 5, 2018 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced an agreement to sell its India medical diagnostics business to Strand Life Sciences, a Bangalore-based specialized diagnostics company. "This acquisition is an important addition to our network of 24 diagnostic labs across India, especially as we continue to expand our work in oncology, genomics, and precision medicine," said Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences. Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics, commented: "We have built a diagnostic laboratory in India with a reputation for quality over the past 10 years.
With the rising need for AP and molecular oncology services in healthcare, we consider the acquisition of PhenoPath by Quest Diagnostics (DGX) to be well-timed and a strategic fit for its portfolio.
Quest Diagnostics based the results on the general workforce, excluding workers such as train conductors whose drug tests are federally-mandated.
On the 22 October 2018, Quest Diagnostics Incorporated (NYSE:DGX) will be paying shareholders an upcoming dividend amount of US$0.50 per share. However, investors must have bought the company’s stock before Read More...
In this article I am going to calculate the intrinsic value of Quest Diagnostics Incorporated (NYSE:DGX) by taking the expected future cash flows and discounting them to their present value. Read More...
Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.
PhenoPath deepens Quest's presence in the Pacific Northwest while extending the company's capabilities in anatomic pathology and molecular oncology SECAUCUS, N.J. and SEATTLE , Sept. 27, 2018 /PRNewswire/ ...
SECAUCUS , N.J. and ANNISTON, Ala., Sept. 26, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Regional Medical Center Health System ...
Quest Diagnostics' (DGX) acquisition of ReproSource lies in tandem with the company's accelerated growth strategy, especially in advanced diagnostics.
The acquisition, once completed, will include the T-SPOT®.TB tuberculosis and the Accutix™ tick-borne disease testing services provided by Oxford Immunotec's laboratories in Memphis, TN, and Norwood, MA. As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest Diagnostics under the terms of a long-term supply agreement, which would be effective at closing of the acquisition.
Bolsters Quest's leadership in advanced diagnostics for women's and reproductive health SECAUCUS, N.J. and WOBURN, Mass. , Sept. 24, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading ...
In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.